Subclinical hypothyroidism and metabolic syndrome in psychiatric patients: A systematic literature review and meta-analysis.

IF 1.2 4区 医学 Q4 PSYCHIATRY
Australasian Psychiatry Pub Date : 2024-10-01 Epub Date: 2024-07-24 DOI:10.1177/10398562241267149
The The Aung, Win Wah, Arnob Chakraborti, Vikas Garg
{"title":"Subclinical hypothyroidism and metabolic syndrome in psychiatric patients: A systematic literature review and meta-analysis.","authors":"The The Aung, Win Wah, Arnob Chakraborti, Vikas Garg","doi":"10.1177/10398562241267149","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The systematic review evaluated the association of subclinical hypothyroidism (SCH) with metabolic syndrome (MetS) and specific MetS components in people with major psychiatric disorders.</p><p><strong>Methods: </strong>A systematic review and meta-analysis was conducted to evaluate the association of SCH with MetS and its components in people with major psychiatric conditions.</p><p><strong>Results: </strong>Five studies incorporating 24,158 participants met the inclusion criteria. All five studies comprised patients with depression and/or anxiety. Three studies incorporating 3365 participants were suitable for the meta-analysis. The pooled Odds Ratio (OR) of MetS was 3.46 (95% Confidence Interval/CI = 1.39-8.62) in major depressive disorder (MDD) and anxiety disorders patients with concurrent SCH compared to those without SCH. Meta-analysis showed a significant positive association between SCH and high body mass index (OR = 2.58, 95%CI = 1.33-5.01), high fasting plasma glucose (OR = 3.05, 95%CI = 1.79-5.18) and low high-density lipoprotein cholesterol (OR = 2.30, 95%CI = 1.82-2.92).</p><p><strong>Conclusions: </strong>These findings suggest a significant positive association between MetS and SCH in people with MDD and anxiety disorders. This review informed the clinical implications of MetS in MDD with comorbid SCH and the importance of early diagnosis and treatment for SCH and MetS in psychiatric patients.</p>","PeriodicalId":8630,"journal":{"name":"Australasian Psychiatry","volume":" ","pages":"470-476"},"PeriodicalIF":1.2000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australasian Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10398562241267149","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/24 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The systematic review evaluated the association of subclinical hypothyroidism (SCH) with metabolic syndrome (MetS) and specific MetS components in people with major psychiatric disorders.

Methods: A systematic review and meta-analysis was conducted to evaluate the association of SCH with MetS and its components in people with major psychiatric conditions.

Results: Five studies incorporating 24,158 participants met the inclusion criteria. All five studies comprised patients with depression and/or anxiety. Three studies incorporating 3365 participants were suitable for the meta-analysis. The pooled Odds Ratio (OR) of MetS was 3.46 (95% Confidence Interval/CI = 1.39-8.62) in major depressive disorder (MDD) and anxiety disorders patients with concurrent SCH compared to those without SCH. Meta-analysis showed a significant positive association between SCH and high body mass index (OR = 2.58, 95%CI = 1.33-5.01), high fasting plasma glucose (OR = 3.05, 95%CI = 1.79-5.18) and low high-density lipoprotein cholesterol (OR = 2.30, 95%CI = 1.82-2.92).

Conclusions: These findings suggest a significant positive association between MetS and SCH in people with MDD and anxiety disorders. This review informed the clinical implications of MetS in MDD with comorbid SCH and the importance of early diagnosis and treatment for SCH and MetS in psychiatric patients.

精神病患者亚临床甲状腺功能减退症和代谢综合征:系统性文献综述和荟萃分析。
目的该系统综述评估了亚临床甲状腺功能减退症(SCH)与代谢综合征(MetS)以及主要精神疾病患者代谢综合征的特定组成部分之间的关系:我们进行了一项系统综述和荟萃分析,以评估亚临床甲状腺机能减退(SCH)与主要精神疾病患者的代谢综合征(MetS)及其组成部分之间的关系:共有五项研究纳入了 24,158 名参与者,符合纳入标准。这五项研究的对象均为抑郁症和/或焦虑症患者。有三项研究纳入了 3365 名参与者,适合进行荟萃分析。与没有并发SCH的重度抑郁症(MDD)和焦虑症患者相比,并发SCH的重度抑郁症(MDD)和焦虑症患者中MetS的总比值比(OR)为3.46(95% 置信区间/CI = 1.39-8.62)。Meta分析表明,SCH与高体重指数(OR = 2.58,95%CI = 1.33-5.01)、高空腹血浆葡萄糖(OR = 3.05,95%CI = 1.79-5.18)和低高密度脂蛋白胆固醇(OR = 2.30,95%CI = 1.82-2.92)之间存在显著的正相关关系:这些研究结果表明,MetS与MDD和焦虑症患者的SCH之间存在明显的正相关关系。这篇综述揭示了MetS对合并SCH的MDD患者的临床意义,以及精神病患者早期诊断和治疗SCH和MetS的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Australasian Psychiatry
Australasian Psychiatry 医学-精神病学
CiteScore
2.80
自引率
5.60%
发文量
159
审稿时长
6-12 weeks
期刊介绍: Australasian Psychiatry is the bi-monthly journal of The Royal Australian and New Zealand College of Psychiatrists (RANZCP) that aims to promote the art of psychiatry and its maintenance of excellence in practice. The journal is peer-reviewed and accepts submissions, presented as original research; reviews; descriptions of innovative services; comments on policy, history, politics, economics, training, ethics and the Arts as they relate to mental health and mental health services; statements of opinion and letters. Book reviews are commissioned by the editor. A section of the journal provides information on RANZCP business and related matters.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信